# US 2015/0104416 A1 · Leukemic Stem Cell Ablation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104416 A1
- Document ID: US20150104416A1
- Status: Published application
- Kind: A1
- Application number: 14/574,989
- Filed: 2014-12-18
- Published: 2015-04-16
- Earliest claimed: 2007-12-07
- Assignees: ChemGenex Pharmaceuticals, Inc.
- Applicants: Chemgenex Pharmaceuticals, Inc.
- Inventors: Dennis Brown
- Web page: https://patentgrep.com/patent/US20150104416A1

## CPC

- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating a leukemia patient that is resistant to a thymidine kinase inhibitor (TKI) other than imantinib comprising administering a cephalotaxine to said patient until said patient demonstrates a hematological or cytological response to said leukemia.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method for treating a patient with leukemia that is resistant to dasatinib, said method comprising:
administering omacetaxine mepesuccinate to said patient until said patient demonstrates a hematological or cytological response.

### Claim 21 (depends on 20)

The method of claim 20 further comprising administering an additional anti-leukemia agent.

### Claim 22 (depends on 21)

The method of claim 21 wherein said additional anti-leukemia agent is selected from tyrosine kinase inhibitors, SRC-kinase inhibitors, aurora kinase inhibitors, interferon alpha, hydroxyurea, ara-C or doxorubicin.

### Claim 23 (depends on 21)

The method of claim 21 wherein omceataxine mepesuccinate is administered before said additional anti-leukemia agent.

### Claim 24 (depends on 21)

The method of claim 21 wherein omacetaxine mepesuccinate is administered after said additional anti-leukemia agent.

### Claim 25 (depends on 21)

The method of claim 21 wherein omacetaxine mepesuccinate is administered contemporaneously with said additional anti-leukemia agent.

### Claim 26 (depends on 25)

The method of claim 25 wherein said additional anti-leukemia agent is a tyrosine kinase inhibitor, SRC-kinase inhibitor, or aurora kinase inhibitor.

### Claim 27

A method for treating a patient with leukemia that is resistant to bosutinib, said method comprising:
(a) administering omacetaxine mepesuccinate to said patient until said patient demonstrates a hematological or cytological response.

### Claim 28 (depends on 27)

The method of claim 27 further comprising administering an additional anti-leukemia agent.

### Claim 29 (depends on 28)

The method of claim 28 wherein said additional anti-leukemia agent is selected from tyrosine kinase inhibitors, SRC-kinase inhibitors, aurora kinase inhibitors, interferon alpha, hydroxyurea, ara-C or doxorubicin.

### Claim 30 (depends on 28)

The method of claim 28 wherein omceataxine mepesuccinate is administered before said additional anti-leukemia agent.

### Claim 31 (depends on 28)

The method of claim 28 wherein omacetaxine mepesuccinate is administered after said additional anti-leukemia agent.

### Claim 32 (depends on 28)

The method of claim 28 wherein omacetaxine mepesuccinate is administered contemporaneously with said additional anti-leukemia agent.

### Claim 33 (depends on 32)

The method of claim 32 wherein said additional anti-leukemia agent is a tyrosine kinase inhibitor, SRC-kinase inhibitor, or aurora kinase inhibitor.

### Claim 34

A method for treating a patient with leukemia that is resistant to at least one of dasatinib or bosutinib, said method comprising administering omacetaxine mepesuccinate to said patient.

### Claim 35 (depends on 34)

The method of claim 34 wherein omacetaxine mepesuccinate is administered subcutaneously.

### Claim 36 (depends on 34)

The method of claim 34 further comprising administering an additional anti-leukemia agent to said patient before, during, or after administration of omacetaxine mepesuccinate.

### Claim 37 (depends on 34)

The method of claim 34 wherein omacetaxine mepesuccinate is administered for 5 days or more.

### Claim 38 (depends on 34)

The method of claim 34 wherein said leukemia is also resistant to imatinib and/or nilotinib.

### Claim 39

A method for treating a patient with leukemia that is resistant to dasatinib or bosutinib, said method comprising:
(a) administering omacetaxine mepesuccinate to said patient in an amount of about 1.0 to about 5.0 mg/m2.

### Claim 40 (depends on 20, 27)

A method according to claim 20 or 27 wherein said administration is twice daily for seven days.

### Claim 41 (depends on 40)

A method according to claim 40 wherein the dose of said omacetaxine mepesuccinate is 1.25 mg/m2.

### Claim 42 (depends on 40)

A method according to claim 40 wherein said omacetaxine mepesuccinate is administered for 14 days.

### Claim 43 (depends on 41)

A method according to claim 41 wherein said omacetaxine mepesuccinate is administered for 14 days.
